Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insmed Growth Agent iPlex Joins Tercica's Increlex With Orphan Drug Designation

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves iPlex for the same indication as Increlex, but both products are granted orphan drug exclusivity.

You may also be interested in...



Insmed Growth Treatment iPlex Enters Market

Mecasermin rinfabate injection will compete with Tercica’s Increlex.

Insmed Growth Treatment iPlex Enters Market

Mecasermin rinfabate injection will compete with Tercica’s Increlex.

Tercica’s Growth Treatment Increlex Clears FDA With Orphan Drug Exclusivity

The company plans to launch the extreme short stature therapy in January with a 30-member sales force.

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel